Published in Medical Letter on the CDC and FDA, December 26th, 2004
"We are pleased by the FDA's decision, which clears the way for us to begin enrolling patients in this clinical trial," said Carol A. Ammon, chairman and chief executive officer. "We now believe we will be in a position to file our complete response to the FDA's approvable letter for oxymorphone ER in early...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA